LifeStance Q3 revenue $312.7M (+19% YoY); raises FY2024 guidance on Adj. EBITDA to $105-115M

LifeStance Health Group, Inc.

Revenue $312.7M (+19% YoY); net loss improved to $6.0M from $61.6M; Adjusted EBITDA $30.7M (+110%).
Clinician base 7,269 (+13% YoY); visit volumes 2.0M (+15%); Center Margin $100.4M (32.1% of revenue, +32%).
FY2024 guidance raised: revenue $1.228B-$1.248B; Adj. EBITDA $105M-$115M; positive Free Cash Flow reiterated.
Q4 2024 guidance: revenue $302.5M-$322.5M; Adj. EBITDA $18M-$28M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.